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ity and ﬁt better. As a measure of quality of the ﬁtted model
we have chosen the Deviance Information Criteria (DIC). The
improvement in the deviance of the model for the number of
principles per patient is of 1790 and in DIC of 1760. The maps
reveal geographical inequalities and zones with greater average
values. CONCLUSION: The Bayesian hierarchical models have
been a very useful tool for incorporating geographical informa-
tion in the analysis of pharmacological prescription data. They
allow mapping spatial components expressing the trend of that
geographical variation.
PAR29
AZATHIOPURINE,TPMT POLYMORPHISMS AND ADRS:
THE COST OF NEUTROPENIA
Compagni A1, Bartoli S1, Gutierrez de Mesa E2, Ibarreta D3
1University of Bocconi, Milan, Italy, 2European Commission, DG-JRC,
Seville, Spain, 3Institute for Prospective Technological Studies,
JRC-European Commission, Seville, Spain
OBJECTIVES: Pharmacogenetics holds the promise of pre-
venting adverse drug events (ADRs) but the diffusion of these
diagnostic testsis still limited. Assessing cost-effectiveness of
pharmacogenetic interventions, a key to successful clinical imple-
mentation, requires access to data on ADRs and related costs
which are not readily available. This study focuses on ADRs
induced by azathioprine (AZA) treatment in Rheumatoid Arthri-
tis and Inﬂammatory Bowel Disease patients, for whom there is
a recognized association between the occurrence of severe neu-
tropenia and the diminished activity of TPMT. The study aims at
evaluating the availability and quality of cost data related to: (i)
the treatment and management of ADRs induced by AZA and (ii)
the use of TPMT diagnostic kits in an average laboratory. The
overall objective is to review the possibility of building a cost-
effectiveness model on European data. METHODS: A literature
review was conducted on PubMED and Embase databases.. The
clinical path for the management of AZA-induced ADRs was
elaborated with an international panel of gastroenterologists/
rheumatologists. RESULTS: Very few studies describe costs of
treating ADRs induced by AZA. When present, costs are rarely
collected empirically but derived from national tariff databases
or from a single health care organization, resulting in a large
variability. Reported costs are only direct, disregarding produc-
tivity losses, while ADRs often require hospitalization. Direct
annual costs for ADRs range from €476 to €5505. It is equally
difﬁcult to identify solid data on the costs o TPMT diagnostic
tests in an average European laboratory, with estimates between
70€ and 130€. CONCLUSION: Cost-effectiveness data might
inﬂuence the degree of conﬁdence of health care organizations in
adopting new technologies. Published economic studies that
evaluate TPMT diagnostic tests and the costs they might prevent
are still rather weak. Prospective economic studies, that system-
atically include the evaluation of ADR costs, are urgently needed.
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OBJECTIVES: To evaluate switching patterns among anti-tumor
necrosis factor therapies (anti-TNFs) in rheumatoid arthritis
(RA) patients. METHODS: A retrospective patient chart review
study was conducted in six rheumatology clinics across the US.
The ﬁrst anti-TNF encounter among RA patients between 2002
and 2004 was identiﬁed. Patients were required to have a
minimum of 12 months of continuous records prior to and
following their index biologic date. Three mutually exclusive
cohorts were developed based on biologic therapy: inﬂiximab,
etanercept or adalimumab. Switching was deﬁned as discontinu-
ation of the index anti-TNF and initiation of another anti-TNF
agent. The rates of switching and time before switching were
examined. RESULTS: Of 496 patients analyzed, 266 (53.6%)
received inﬂiximab, 146 (29.4%) received etanercept, and 84
(14.1%) received adalimumab. 74% of patients were female,
with an average age of 56.1 years. Overall, 87 (17.5%) patients
switched anti-TNF therapy during the follow-up period.
Patients in the inﬂiximab group had a lower switch rate (31
patients, 11.7%) compared with patients in the etanercept (38
patients, 26%) and adalimumab (18 patients, 21.4%) groups.
Chi-Square analyses indicated the differences among three
groups were statistically signiﬁcant (p < 0.001). The inﬂiximab
group had a longer average time before switching (342 days),
compared with those in the etanercept (266 days) and adali-
mumab (341 days) groups; (p = ns). Lack of effectiveness and
safety concerns were the most common reasons for switching
(28.6%). CONCLUSION: The switching rate and time before
switching are important measures of the effectiveness of RA
treatment in real world practice. This chart review study found
that inﬂiximab is associated with a lower switching rate and
longer time before switching, as compared with etanercept
and adalimumab, both of which had higher switching rates and
shorter time to switching. Further studies to evaluate the asso-
ciation of switching with clinical, economic, and humanistic
outcomes are recommended.
ARTHRITIS—Methods and Concepts
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OBJECTIVES: Analysis of functional data from longitudinal
studies is usually complicated by missing data. The use of
repeated measures ANOVA for statistical analysis tends to
decrease the sample size and thus affect power and signiﬁcance
of the results. The present study aims to address this problem
with use of hierarchical regression or multilevel modeling.
METHODS: We analysed functional results of 4777 patients
following hip resurfacing arthroplasty. These patients were fol-
lowed annually using Harris Hip score and Merle d’Aubigné
score. Individual domains of Pain, mobility and range of move-
ment were recorded. The scores comprised a follow up period of
nine years with some missing values. The data was analysed
using multilevel techniques in statistical package SYSTAT 11.0.
Model was ﬁtted at two levels, with level one being the scores
and level two the patients. RESULTS: In all the domains of
function, pain and movement, pre operative score and gender
were signiﬁcantly associated with post operative hip function
(p <= 0.05). A better pre op score predicted a better post op score
and male gender was associated with better overall function.
There was a consistent inverse relationship of overall functional
improvement with individual domains of pain and movement.
This implied that a good pre-operative pain score will have less
improvement over time as compared to a poor pre-operative pain
score. There was no signiﬁcant effect of age on the overall func-
tional results (p = 0.492). CONCLUSION: Functional outcome
A252 Abstracts
